Skip to main content

Advertisement

ADVERTISEMENT

Acute Myeloid Leukemia News

News
02/08/2024

Jordan Kadish

Jordan Kadish
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of...
02/08/2024
Oncology

Advertisement